Humana Inc. vs Kia Corporation: Strategic Comparison

This in-depth comparison examines Humana Inc. and Kia Corporation across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Humana Inc. on its own, evaluating Kia Corporation, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Humana Inc. and Kia Corporation is widest.

On the headline numbers, Humana Inc. reports annual revenue of $129.7B against ~$81B for Kia Corporation, while their respective market capitalizations stand at $48.2B and $32.4B. Humana Inc. is headquartered in United States and Kia Corporation in South Korea, and those different home markets shape how each company competes.

Humana Inc.: Humana Inc. is a Fortune 50 health company headquartered in Louisville, Kentucky. It serves roughly 7.2 million individual and group Medicare Advantage members, millions of stand-alone Part D, Medicaid, and TRICARE beneficiaries, and patients of its CenterWell clinics, pharmacy, and home health services. Unlike diversified rivals, Humana gets nearly all of its medical membership from government-funded programs, so it is effectively a bet on Medicare Advantage and senior care.

Kia Corporation: Kia Corporation (KRX: 000270), headquartered at 12 Heolleung-ro, Seocho-gu, Seoul, is the second automaker in Hyundai Motor Group. It has been listed since July 1973. Hyundai Motor Company holds 35.17% of its shares, and Hyundai and its related parties hold 36.99% together. Foreign investors own 40.32% and Korea's National Pension Service owns 7.25% (end of 2025). Kia designs and markets its vehicles separately from Hyundai, but the two share engineering, platforms and suppliers. In 2025 it sold 3,135,873 vehicles, its best year so far. The best sellers were the Sportage, Seltos, Sorento and Carnival, along with a growing range of hybrid and EV models.

Humana Inc. and Kia Corporation pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Humana Inc. and Kia Corporation.

Humana Inc. business model: Humana runs two reporting segments. The Insurance segment sells individual and group Medicare Advantage plans, stand-alone Medicare Part D drug plans, state Medicaid contracts, and administers TRICARE for the Defense Health Agency. It is paid largely by the federal government on a per-member, per-month basis adjusted for each member's health risk, and keeps the difference between those premiums and medical and pharmacy claims plus operating costs. The CenterWell segment provides services: CenterWell Senior Primary Care clinics, CenterWell Pharmacy (mail-order and specialty), and CenterWell Home Health. CenterWell serves Humana members and members of other plans, and it gives Humana direct influence over care costs for its own seniors.

Kia Corporation business model: Kia makes money mainly by building and selling vehicles wholesale to its regional sales subsidiaries, importers and franchised dealers, which then sell to retail and fleet buyers. SUVs and RVs such as the Sportage, Sorento, Seltos, Carnival and Telluride make up most of the mix and earn more per unit than small sedans. Parts, accessories, service and connected-car subscriptions (Kia Connect) bring in further revenue from cars already on the road. Kia shares platforms, powertrains, the 800-volt E-GMP EV architecture and many suppliers with Hyundai Motor, which spreads engineering costs across both brands. Hyundai Mobis and Hyundai WIA are its biggest related-party suppliers: Kia's 2025 transactions with them were about $6.67 billion (KRW 9.4 trillion) and ~$2.63 billion (KRW 3.7 trillion). Hyundai Capital provides much of the retail and dealer financing. A newer line of business is purpose-built vehicles (PBVs), starting with the PV5 electric van, which are sold to businesses for delivery, ride-hailing and fleet use.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Humana Inc. stack up against those of Kia Corporation.

Humana Inc. competitive advantage: Humana's edge is depth in one market. It is the second-largest Medicare Advantage insurer after UnitedHealth, it has decades of experience pricing senior risk, and it owns care-delivery assets built for seniors: CenterWell Senior Primary Care clinics, a large mail-order pharmacy, and CenterWell Home Health. Owning those services lets Humana manage chronic conditions and pharmacy spending directly instead of only paying claims. The tradeoff is concentration: unlike UnitedHealth, CVS/Aetna, or Elevance, it has no large commercial or PBM business to offset a bad Medicare year.

Kia Corporation competitive advantage: Kia's main advantages are its scale inside Hyundai Motor Group and the way it can switch powertrains easily. Sharing platforms, the E-GMP 800V EV architecture, batteries, chips and logistics (Hyundai Glovis) with Hyundai lowers development and purchasing costs. Factories in Korea, the US (Georgia), Mexico, Slovakia and India let Kia shift production between combustion, hybrid and electric models. In the US, the 10-year/100,000-mile powertrain warranty and award-winning models (EV6, EV9, Telluride) have built buyer trust that its 1990s cars never had.

Future prospects matter as much as current results. The growth strategies below explain how Humana Inc. and Kia Corporation each plan to expand from here.

Humana Inc. growth strategy: Humana's strategy under Jim Rechtin is to grow Medicare Advantage membership while rebuilding margins and quality scores. Key moves include completing the exit from employer-group commercial medical coverage in 2025, adding more than 1 million MA members for 2026, pruning about 600,000 members' worth of underperforming plans for 2027, investing in Star Ratings operations, and expanding CenterWell Senior Primary Care and CenterWell Pharmacy so that more member care runs through Humana-owned services. It is also bidding for and growing state Medicaid contracts, with a focus on members eligible for both Medicare and Medicaid.

Kia Corporation growth strategy: Kia's current strategy, set out at the 2026 CEO Investor Day, uses several powertrains instead of only EVs. It plans to grow EVs (EV3, EV4, EV5, EV6, EV9 and later models) and hybrids together, add a PBV line of modular electric vans starting with the PV5, and build up software-defined vehicles, autonomous driving and robotics as longer-term businesses. By 2030 it is targeting 1.02 million sales in the US and 746,000 in Europe, along with growth in India and other emerging markets.

A closer look at the financial trajectory of Humana Inc. and Kia Corporation rounds out the comparison.

Humana Inc.: Humana's revenue grew from $54.4 billion in 2016 to $129.66 billion in 2025, driven by Medicare Advantage enrollment and higher per-member payments. Profit moved the other way: net income fell from $3.37 billion in 2020 to $1.21 billion in 2024 and $1.19 billion in 2025 as medical costs rose faster than payments. In 2026 revenue is growing fast again: Q2 2026 revenue was $40.89 billion, up 26.2% year over year, with GAAP EPS of $5.73 and adjusted EPS of $7.61. Year-to-date operating cash flow reached $3.22 billion. Full-year 2026 guidance is adjusted EPS of at least $9.00 and GAAP EPS of at least $6.52, reflecting the Star Ratings bonus headwind.

Kia Corporation: Kia's revenue has risen every year since 2020: from ~$49.6 billion (KRW 69.9 trillion) in 2021 to ~$76.3 billion (KRW 107.4 trillion) in 2024 and a record ~$81 billion (KRW 114.1 trillion) in 2025 (+6.2%). Profit has not kept up. Operating profit fell 28.3% in 2025 to ~$6.45 billion (KRW 9.08 trillion), and the margin dropped from 11.8% to 8.0% as US tariffs and incentives ate into earnings. Net profit was about $5.36 billion (KRW 7.55 trillion). The squeeze continued into 2026. Q1 revenue was a record ~$20.9 billion (KRW 29.50 trillion) (+5.3%), but operating profit fell 26.7% to ~$1.57 billion (KRW 2.21 trillion). Q2 revenue reached ~$23.5 billion (KRW 33.04 trillion) (+12.6%) while operating profit fell 4.9% to ~$1.87 billion (KRW 2.63 trillion). The shares dropped about 13% on the day of the Q2 results. Shareholder returns are still high: the 2025 dividend was KRW 6,800 per share, a 35% consolidated payout ratio, and Kia has been cancelling treasury shares, cutting issued shares from 405.4 million in 2022 to 390.4 million at the end of 2025.